Stay updated with breaking news from Expanded Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Mr. Adi Frish,...
– Data being presented show long-term benefits of Bylvay in children with PFIC – – First potential non-invasive treatment option that could transform the ...
TEL AVIV, Israel and RALEIGH, N.C., May 27, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the first quarter ended March 31, 2021. Dror Ben-Asher, RedHill's Chief Executive Officer, said: "The progress of our two novel, oral COVID-19 programs has put RedHill at the forefront of oral COVID-19 therapeutics development. Opaganib, one of the most advanced and promising novel, dual-mode of action, oral drug candidates in development for COVID-19, now ...
Share this article Share this article TEL AVIV, Israel and RALEIGH, NC, May 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced receipt of two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) covering opaganib [1] and RHB-107 (upamostat) [2] as methods for the treatment of COVID-19 caused by the SARS-CoV-2 virus. Both opaganib and RHB-107 are novel COVID-19 therapeutic candidates, in oral pill form, with dual mechanism of action effects. Both are host-targeted and are therefor...
RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021 USA - English Two new analyses of Movantik® (naloxegol) data, from almost 900 patients, were presented at Digestive Disease Week 2021 evaluating the onset of action and symptom improvement of Movantik for a broad range of challenging opioid-induced constipation (OIC) symptoms Movantik is an oral peripherally acting mu-opioid receptor antagonist (PAMORA) approved in the U.S. to treat OIC in adult patients with chronic non-cancer pain News provided by Share this article Share this article TEL AV...